GB201914040D0 - Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody - Google Patents
Dosage regimes for the administration of lag-3/pd-l1 bispecific antibodyInfo
- Publication number
- GB201914040D0 GB201914040D0 GB201914040A GB201914040A GB201914040D0 GB 201914040 D0 GB201914040 D0 GB 201914040D0 GB 201914040 A GB201914040 A GB 201914040A GB 201914040 A GB201914040 A GB 201914040A GB 201914040 D0 GB201914040 D0 GB 201914040D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- lag
- administration
- bispecific antibody
- dosage regimes
- regimes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201914040A GB201914040D0 (en) | 2019-09-30 | 2019-09-30 | Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody |
| SG11202112136RA SG11202112136RA (en) | 2019-05-14 | 2020-05-14 | Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody |
| PCT/EP2020/063529 WO2020229626A1 (en) | 2019-05-14 | 2020-05-14 | Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody |
| CN202080051441.8A CN114206939A (en) | 2019-05-14 | 2020-05-14 | Dosage regimen for administration of LAG-3/PD-L1 bispecific antibodies |
| EP20726768.3A EP3969477A1 (en) | 2019-05-14 | 2020-05-14 | Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody |
| US17/610,873 US20220275092A1 (en) | 2019-05-14 | 2020-05-14 | Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody |
| JP2021566974A JP2022533578A (en) | 2019-05-14 | 2020-05-14 | Dosage Regimens for Administration of LAG-3/PD-L1 Bispecific Antibodies |
| BR112021022831A BR112021022831A2 (en) | 2019-05-14 | 2020-05-14 | Dosage regimens for the administration of a lag-3/pd-11 bispecific antibody |
| MX2021013943A MX2021013943A (en) | 2019-05-14 | 2020-05-14 | Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody. |
| AU2020275209A AU2020275209A1 (en) | 2019-05-14 | 2020-05-14 | Dosage regimes for the administration of a LAG-3/PD-L1 bispecific antibody |
| CA3139003A CA3139003A1 (en) | 2019-05-14 | 2020-05-14 | Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody |
| KR1020217040782A KR20220008316A (en) | 2019-05-14 | 2020-05-14 | Dosage regimen for administration of LAG-3/PD-L1 bispecific antibodies |
| IL287979A IL287979A (en) | 2019-05-14 | 2021-11-10 | Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201914040A GB201914040D0 (en) | 2019-09-30 | 2019-09-30 | Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201914040D0 true GB201914040D0 (en) | 2019-11-13 |
Family
ID=68538968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB201914040A Ceased GB201914040D0 (en) | 2019-05-14 | 2019-09-30 | Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB201914040D0 (en) |
-
2019
- 2019-09-30 GB GB201914040A patent/GB201914040D0/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3476399A4 (en) | Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof | |
| MA44145A (en) | BISPECIFIC ANTI-CD20 / ANTI-CD3 ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA | |
| IL276872A (en) | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies | |
| MA44146A (en) | COMBINATION OF ANTI-PD-1 AND BISPECIFIC ANTI-CD20 / ANTI-CD3 ANTIBODIES TO TREAT CANCER | |
| MX2018005720A (en) | Pd-l1 antibody, antigen fragment binding thereof and pharmaceutical use thereof. | |
| MA43365A (en) | ANTI-DR5 ANTIBODIES AND METHODS FOR USING THE SAME | |
| MA43197A (en) | BISPECIFIC ANTIBODY CONSTRUCTIONS FOR CDH3 AND CD3 | |
| IL271245A (en) | Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues | |
| IL287979A (en) | Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody | |
| ZA202004907B (en) | Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| ZA202206885B (en) | Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof | |
| IL278889A (en) | Dosing regimen for the treatment of pi3k related disorders | |
| EP3877418A4 (en) | Dosing regimen of anti-tigit antibody for treatment of cancer | |
| IL290256A (en) | Anti-pd-1 antibody and pharmaceutical use thereof | |
| EP3842071A4 (en) | Use of tim-3 antibody in preparation of medicines for treating tumors | |
| EP3916016A4 (en) | Novel bispecific antibody molecule and bispecific antibody simultaneously combining pd-l1 and lag-3 | |
| EP4074338A4 (en) | Stable anti-pd-1 antibody pharmaceutical preparation | |
| IL285134A (en) | Therapeutic antibody formulation | |
| EP3957326A4 (en) | Use of anti-pd-1 antibody in preparation of medicament for treating solid tumors | |
| EP3647323A4 (en) | Anti-gitr antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| GB201914040D0 (en) | Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody | |
| GB202000318D0 (en) | Dosage regimes for the administration of LAG-3/PD-L1 bispecific antibody | |
| IL291432A (en) | Dosing for anti-tryptase antibodies | |
| EP3699192A4 (en) | Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same | |
| GB201906807D0 (en) | Dosages regimes for the administration of lag-3/pd-l1 bispectic antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |